.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,989,474

« Back to Dashboard
Patent 7,989,474 protects OFEV and is included in one NDA.

This patent has eight patent family members in ten countries.

Summary for Patent: 7,989,474

Title:Use of Lck inhibitors for treatment of immunologic diseases
Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
Inventor(s): Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Hilberg; Frank (Vienna, AT), Hauptmann; Rudolf (Ebreichsdorf, AT), Stefanic; Martin Fredrich (Warthausen-Birkenhard, DE), Colbatzky; Florian (Stafflangen, DE), Ernest; Steffan (Moelnlycke, SE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:12/334,323
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 16th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXNo7,989,474► subscribe TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYes7,989,474► subscribe TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,989,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 37 423Aug 16, 2002

International Patent Family for Patent: 7,989,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2006514611► subscribe
Portugal1530466► subscribe
Slovenia1530466► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc